Accumulation of identical T cells in melanoma and vitiligo-like leukoderma

Journal of Investigative Dermatology

Volumn 113, Issue 6, 1999, Pages 1033-1038

  Becker, Jürgen C ^a,b   Guldberg, Per ^b   Zeuthen, Jesper ^b   Bröcker, Eva Bettina ^a   Straten, Per Thor ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Melanocyte differentiation antigens; Melanocytes; T cell receptor; Tumor associated antigens

Indexed keywords

TUMOR ANTIGEN;

ANTIGEN RECOGNITION; ARTICLE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOLOGY; LEUKODERMA; MELANOMA; MOLECULAR CLONING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL CULTURE; TUMOR REJECTION; VITILIGO;

EID: 0033397388     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.1999.00805.x     Document Type: Article

References (26)

1. Altman JD, Moss PH, Goulder PR, et al: Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94-96, 1996
2. Becker JC, Varki N, Brocker EB, Reisfeld RA: Lymphocyte-mediated alopecia in C57BL/6 mice following successful immunotherapy for melanoma. J Invest Dermatol 107:627-632, 1996a
3. Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA: Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest 98:2801-2804, 1996b
4. Becker JC, Terheyden P, Brockcr EB: Molecular basis of T-cell dysfunction in melanoma. Melanoma Res 7:S51-S57, 1997
5. Chen L: Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol Today 19:27-30, 1998
6. Faure F, Even J, Kourilsky P: Tumor-specific immune response: current in vitro analyses may not reflect the in vivo immune status. Crit Rev Immunol 18:77-86, 1998
7. Ferradini L, Mackensen A, Genevee C, Bosq J, Duvillard P, Avril MF, Hercend T: Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J Clin Invest 91:1183-1190, 1993
8. Gapin L, Fukui Y, Kanellopoulos J, et al: Quantitative analysis of the T cell repertoire selected by a single peptidc-major histocompatibility complex. J Exp Med 187:1871-1883, 1998
9. Hara I, Takechi Y, Houghton AN: Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 182:1609-1614, 1995
10. Kirkin AF, Dzhandzhugazyan K, Zeuthen J: The immunologic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes. Exp Clin Immunogenet 15:19-32, 1998
11. Le-Poole IC, van den Wijngaard RM, Westerhof W, Das PK: Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 148:1219-1228, 1996
12. Mackensen A, Ferradini L, Carcelain G, Triebel F, Faure F, Viel S, Hercend T: Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res 53:3569-3573, 1993
13. Musette P, Bachelez H, Flageul B, Delarbre C, Kourilsky P, Dubertret L, Gachelin G: Immune-mediated destruction of melanocytes in halo nevi is associated with the local expansion of a limited number of T cell clones. J Immunol 162:1789-1794, 1999
14. Ogg GS, Rod DP, Romero P, Chen JL, Cerundolo V: High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 188:1203-1208, 1998
15. Pardoll DM: Cancer vaccines. Nat Med 4:S525-S531, 1998
16. Rosenberg SA: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18:175-182, 1997
17. Rosenberg SA, White DE: Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 19:81-84, 1996
18. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327, 1998
19. Schoenberger SP, Sercarz EE: Harnessing self-reactivity in cancer immunotherapy. Semin Immunol 8:303-309, 1996
20. Scott AM, Cebon J: Clinical promise of tumour immunology. Lancet 349:SII19-SII22, 1997
21. Sensi M, Parmiani G: Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. Immunol Today 16:588-595, 1995
22. Song YH: Why tyrosinase for treatment of melanoma. Lancet 350:82-83, 1997
23. thor-Straten P, Becker JC, Seremet T, Brocker EB, Zeuthen J: Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma. J Clin Invest 98:279-284, 1996
24. thor-Straten P, Barfoed A, Seremet T, Saeterdal I, Zeuthen J, Guldberg P: Detection and characterization of alpha-beta-T-cell clonality by denaturing gradient gel electrophoresis (DGGE). Biotechniques 25:244-250, 1998
25. thor-Straten P, Guldberg P, Gronbaek K, et al. In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. J Immunol 163:443-447, 1999
26. Van-Parijs L, Abbas AK: Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280:243-248, 1998